
Opinion|Videos|May 14, 2025
Airway Clearance Techniques and Antibiotics for Patients With Bronchiectasis
Panelists discuss how airway clearance devices and techniques, including chest physical therapy, active cycle breathing, exercise, hypertonic saline, and oscillatory positive expiratory pressure devices, are the mainstay of bronchiectasis management.
Advertisement
Episodes in this series

Clinical Brief: Airway Clearance Techniques in Bronchiectasis Management
Main Discussion Topics
- Airway clearance is a mainstay of bronchiectasis management, particularly for symptomatic patients.
- Multiple technique options include manual methods, exercise, devices, and nebulized therapies.
- Pulmonary rehabilitation provides structured exercise support, but access may be challenging.
Key Points for Physicians
- Recommend airway clearance for patients with:
- Chronic productive cough
- Mucus impaction on CT imaging
- Technique options include:
- Manual techniques (chest physical therapy, postural drainage, active cycle breathing)
- Exercise (walking particularly helps with oscillation effects)
- Mechanical devices (positive expiratory pressure devices, high-frequency chest wall oscillation)
- Nebulized hypertonic saline
- Consider pulmonary rehabilitation for patients with limited exercise tolerance.
- Virtual pulmonary rehabilitation may help overcome access barriers.
Notable Insights
Walking exercises are particularly beneficial as heel striking mimics the oscillation that helps mobilize mucus, augmenting airway clearance.
Clinical Significance
A comprehensive airway clearance approach combining multiple techniques is essential for effective bronchiectasis management and preventing exacerbations.
Advertisement
Related to this article

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
5

